Derwent London (LON:DLN) Stock Rating Reaffirmed by Shore Capital

Derwent London (LON:DLN – Get Free Report)‘s stock had its “hold” rating restated by research analysts at Shore Capital in a research report issued to clients and investors on Thursday, Marketbeat.com reports.

Separately, JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of Derwent London in a research report on Thursday, July 20th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the stock. According to data from MarketBeat.com, Derwent London has a consensus rating of “Hold” and a consensus target price of GBX 2,799.75 ($35.78).

Get Derwent London alerts:

Read Our Latest Analysis on Derwent London

Derwent London Trading Down 3.5 %

DLN opened at GBX 2,038 ($26.04) on Thursday. The firm has a market cap of £2.29 billion, a price-to-earnings ratio of -829.60, a PEG ratio of 20.51 and a beta of 0.81. The company has a current ratio of 1.27, a quick ratio of 0.38 and a debt-to-equity ratio of 31.51. Derwent London has a 12 month low of GBX 1,783 ($22.79) and a 12 month high of GBX 2,798 ($35.76). The stock has a fifty day moving average price of GBX 2,126.10 and a 200-day moving average price of GBX 2,317.21.

Derwent London Company Profile

(Get Free Report)

Derwent London plc owns 75 buildings in a commercial real estate portfolio predominantly in central London valued at £5.9 billion as at 30 June 2022, making it the largest London-focused real estate investment trust (REIT). Our experienced team has a long track record of creating value throughout the property cycle by regenerating our buildings via development or refurbishment, effective asset management and capital recycling.

Featured Stories

• Five stocks we like better than Derwent London
• What is a Special Dividend?
• Investing in Coffee: 3 Great Strategies to Consider
• Industrial Products Stocks Investing
• 5 Best Stocks to Buy in a Bear Market
• What Are Dividends? Buy the Best Dividend Stocks
• 3 Pharmaceutical Stocks to Buy and Hold for the Long Haul

Receive News & Ratings for Derwent London Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Derwent London and related companies with MarketBeat.com's FREE daily email newsletter.